We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long Term Extension Study For SPM-005 Participants

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01552538
First Posted: March 13, 2012
Last Update Posted: November 1, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
SetPoint Medical Corporation
  Purpose
This will be an open label multicenter study of the safety and efficacy of an active implantable vagal nerve stimulation (VNS) device in patients with rheumatoid arthritis. Patients who complete study SPM-005 will be enrolled in this study at the time of the last visit of the preceding study.

Condition Intervention Phase
Rheumatoid Arthritis Device: Cyberonics VNS System Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long Term Observational Study of the Safety and Efficacy of an Active Implantable Vagal Nerve Stimulation Device in Patients With Rheumatoid Arthritis

Resource links provided by NLM:


Further study details as provided by SetPoint Medical Corporation:

Primary Outcome Measures:
  • Change in rheumatoid arthritis Disease Activity Score (DAS) from baseline visit [ Time Frame: 12-18 months ]

Secondary Outcome Measures:
  • Subject incidence of Adverse Events [ Time Frame: 12-18 months ]

Estimated Enrollment: 18
Study Start Date: January 2012
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cyberonics VNS System
Continued stimulation w/Cyberonics VNS
Device: Cyberonics VNS System
Stimulation with an active implantable electrical vagal nerve stimulation device

Detailed Description:

This will be an open label multicenter study of the safety and efficacy of an active implantable vagal nerve stimulation (VNS) device in patients with rheumatoid arthritis.

Patients who complete study SPM-005 will be enrolled in this study at the time of the last visit of the preceding study. The assessments at the last visit of the preceding study will also be used as baseline measures for the current study. If the patient has previously discontinued SPM-005 and greater than 30 days have elapsed since the final visit in SPM-005, baseline measures for the current study will be repeated, and an interim medical history will be taken to assess whether any new medical conditions were diagnosed in the time between studies.

Follow-up visits will occur at 3, 6, 12, 18, 24, 36 and 48 months. A final follow-up visit will occur for all remaining patients at study closure when the final enrolled subject has completed 48 months on study.

The study will continue until the last patient entered has completed 48 months in this study.

An Interim Visit or a phone contact must be performed a maximum of 2 months after any change in device settings. Interim visits may also be performed at any time at the investigator's discretion; either between scheduled visits, or after the patient has completed the Month 48 Visit, if the study is still ongoing.

The primary efficacy objective is to determine the long term efficacy of vagal nerve stimulation as assessed by the DAS28 score.

The secondary efficacy objectives are to determine the long term efficacy of vagal nerve stimulation as assessed by:

  • the ACR 20, 50 and 70 response rate,
  • the EULAR response rate, and
  • changes in the Euro-QoL score.

The safety objectives are to determine the long term safely of vagal nerve stimulation as assessed by the subject incidence rates of:

  • Adverse events
  • Serious adverse events
  • Device deficiencies
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have participated in study SPM-005

Exclusion Criteria:

  • Inability to provide informed consent
  • Significant psychiatric illness or substance abuse
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01552538


Locations
Bosnia and Herzegovina
Sveučilišna klinička bolnica Mostar
Mostar, Bosnia and Herzegovina
Klinicki Centar Univerziteta, Reumatologija
Sarajevo, Bosnia and Herzegovina
Croatia
Sisters of Mercy Clinical Hospital Centre
Zagreb, Croatia
Netherlands
Academic Medical Center, University of Amsterdam
Amsterdam, Netherlands
Sponsors and Collaborators
SetPoint Medical Corporation
Investigators
Study Director: Ralph Zitnik, M.D. SetPoint Medical
  More Information

Responsible Party: SetPoint Medical Corporation
ClinicalTrials.gov Identifier: NCT01552538     History of Changes
Other Study ID Numbers: SPM-006
First Submitted: March 9, 2012
First Posted: March 13, 2012
Last Update Posted: November 1, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by SetPoint Medical Corporation:
Rheumatoid Arthritis
Vagus Nerve
Vagal Nerve Stimulation

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases